Literature DB >> 17223273

Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice.

J A Christianson1, J M Ryals, M S Johnson, R T Dobrowsky, D E Wright.   

Abstract

Human diabetic patients often lose touch and vibratory sensations, but to date, most studies on diabetes-induced sensory nerve degeneration have focused on epidermal C-fibers. Here, we explored the effects of diabetes on cutaneous myelinated fibers in relation to the behavioral responses to tactile stimuli from diabetic mice. Weekly behavioral testing began prior to streptozotocin (STZ) administration and continued until 8 weeks, at which time myelinated fiber innervation was examined in the footpad by immunohistochemistry using antiserum to neurofilament heavy chain (NF-H) and myelin basic protein (MBP). Diabetic mice developed reduced behavioral responses to non-noxious (monofilaments) and noxious (pinprick) stimuli. In addition, diabetic mice displayed a 50% reduction in NF-H-positive myelinated innervation of the dermal footpad compared with non-diabetic mice. To test whether two neurotrophins nerve growth factor (NGF) and/or neurotrophin-3 (NT-3) known to support myelinated cutaneous fibers could influence myelinated innervation, diabetic mice were treated intrathecally for 2 weeks with NGF, NT-3, NGF and NT-3. Neurotrophin-treated mice were then compared with diabetic mice treated with insulin for 2 weeks. NGF and insulin treatment both increased paw withdrawal to mechanical stimulation in diabetic mice, whereas NT-3 or a combination of NGF and NT-3 failed to alter paw withdrawal responses. Surprisingly, all treatments significantly increased myelinated innervation compared with control-treated diabetic mice, demonstrating that myelinated cutaneous fibers damaged by hyperglycemia respond to intrathecal administration of neurotrophins. Moreover, NT-3 treatment increased epidermal Merkel cell numbers associated with nerve fibers, consistent with increased numbers of NT-3-responsive slowly adapting A-fibers. These studies suggest that myelinated fiber loss may contribute as significantly as unmyelinated epidermal loss in diabetic neuropathy, and the contradiction between neurotrophin-induced increases in dermal innervation and behavior emphasizes the need for multiple approaches to accurately assess sensory improvements in diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17223273      PMCID: PMC1853280          DOI: 10.1016/j.neuroscience.2006.11.064

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  54 in total

1.  Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies.

Authors:  D N Herrmann; J W Griffin; P Hauer; D R Cornblath; J C McArthur
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

2.  Tactile directional sensibility and diabetic neuropathy.

Authors:  U Norrsell; B Eliasson; M Frizell; B G Wallin; C Wesslau; H Olausson
Journal:  Muscle Nerve       Date:  2001-11       Impact factor: 3.217

3.  Neurotrophin-3 reverses nerve conduction velocity deficits in streptozotocin-diabetic rats.

Authors:  A P Mizisin; N A Calcutt; D R Tomlinson; A Gallagher; P Fernyhough
Journal:  J Peripher Nerv Syst       Date:  1999       Impact factor: 3.494

4.  GDNF rescues nonpeptidergic unmyelinated primary afferents in streptozotocin-treated diabetic mice.

Authors:  S K Akkina; C L Patterson; D E Wright
Journal:  Exp Neurol       Date:  2001-01       Impact factor: 5.330

5.  Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons.

Authors:  Tracy D Wilson-Gerwing; Myles V Dmyterko; Douglas W Zochodne; Jayne M Johnston; Valerie M K Verge
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

6.  Restorative effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice.

Authors:  Julie A Christianson; John T Riekhof; Douglas E Wright
Journal:  Exp Neurol       Date:  2003-02       Impact factor: 5.330

7.  Response properties of mechanoreceptors and nociceptors in mouse glabrous skin: an in vivo study.

Authors:  D M Cain; S G Khasabov; D A Simone
Journal:  J Neurophysiol       Date:  2001-04       Impact factor: 2.714

8.  Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats.

Authors:  G M Khan; S-R Chen; H-L Pan
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

9.  Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia.

Authors:  Tze-Jen Huang; Sally A Price; Lucy Chilton; Nigel A Calcutt; David R Tomlinson; Alex Verkhratsky; Paul Fernyhough
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

Review 10.  Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?

Authors:  Stuart C Apfel
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

View more
  42 in total

1.  Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.

Authors:  Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Yury Maksimchyk; Tamara M Kuchmerovska; Jerry L Nadler; Irina G Obrosova
Journal:  Exp Neurol       Date:  2011-04-16       Impact factor: 5.330

2.  Vitamin D deficiency promotes skeletal muscle hypersensitivity and sensory hyperinnervation.

Authors:  Sarah E Tague; Gwenaëlle L Clarke; Michelle K Winter; Kenneth E McCarson; Douglas E Wright; Peter G Smith
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

3.  Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.

Authors:  Irina G Obrosova; Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Jerry L Nadler; Robert E Schmidt
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 4.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

5.  Excitatory glutamate is essential for development and maintenance of the piloneural mechanoreceptor.

Authors:  Seung-Hyun Woo; Yoshichika Baba; Alexa M Franco; Ellen A Lumpkin; David M Owens
Journal:  Development       Date:  2012-01-12       Impact factor: 6.868

6.  Protection from diabetes-induced peripheral sensory neuropathy--a role for elevated glyoxalase I?

Authors:  M M Jack; J M Ryals; D E Wright
Journal:  Exp Neurol       Date:  2011-12-19       Impact factor: 5.330

7.  Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes.

Authors:  Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan A Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Seth R Bell; John T Groves; Irina G Obrosova
Journal:  Int J Mol Med       Date:  2007-12       Impact factor: 4.101

8.  Early loss of peptidergic intraepidermal nerve fibers in an STZ-induced mouse model of insensate diabetic neuropathy.

Authors:  Megan S Johnson; Janelle M Ryals; Douglas E Wright
Journal:  Pain       Date:  2008-08-30       Impact factor: 6.961

9.  PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.

Authors:  Irina G Obrosova; Weizheng Xu; Valeriy V Lyzogubov; Olga Ilnytska; Nazar Mashtalir; Igor Vareniuk; Ivan A Pavlov; Jie Zhang; Barbara Slusher; Viktor R Drel
Journal:  Free Radic Biol Med       Date:  2007-10-03       Impact factor: 7.376

10.  Engineered zinc finger protein-mediated VEGF-a activation restores deficient VEGF-a in sensory neurons in experimental diabetes.

Authors:  Elizabeth J Pawson; Beatriz Duran-Jimenez; Richard Surosky; Heather E Brooke; S Kaye Spratt; David R Tomlinson; Natalie J Gardiner
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.